Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

255 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastoma.
George SL, Lorenzi F, King D, Hartlieb S, Campbell J, Pemberton H, Toprak UH, Barker K, Tall J, da Costa BM, van den Boogaard ML, Dolman MEM, Molenaar JJ, Bryant HE, Westermann F, Lord CJ, Chesler L. George SL, et al. Among authors: lord cj. EBioMedicine. 2020 Sep;59:102971. doi: 10.1016/j.ebiom.2020.102971. Epub 2020 Aug 23. EBioMedicine. 2020. PMID: 32846370 Free PMC article.
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A. Farmer H, et al. Among authors: lord cj. Nature. 2005 Apr 14;434(7035):917-21. doi: 10.1038/nature03445. Nature. 2005. PMID: 15829967 Free article.
DNA repair deficiency as a therapeutic target in cancer.
Martin SA, Lord CJ, Ashworth A. Martin SA, et al. Among authors: lord cj. Curr Opin Genet Dev. 2008 Feb;18(1):80-6. doi: 10.1016/j.gde.2008.01.016. Epub 2008 Mar 14. Curr Opin Genet Dev. 2008. PMID: 18343102 Review.
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors.
Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, Kim JS, Waldman T, Lord CJ, Ashworth A. Mendes-Pereira AM, et al. Among authors: lord cj. EMBO Mol Med. 2009 Sep;1(6-7):315-22. doi: 10.1002/emmm.200900041. EMBO Mol Med. 2009. PMID: 20049735 Free PMC article.
Therapeutic targeting of the DNA mismatch repair pathway.
Martin SA, Lord CJ, Ashworth A. Martin SA, et al. Among authors: lord cj. Clin Cancer Res. 2010 Nov 1;16(21):5107-13. doi: 10.1158/1078-0432.CCR-10-0821. Epub 2010 Sep 7. Clin Cancer Res. 2010. PMID: 20823149 Review.
The DNA damage response and cancer therapy.
Lord CJ, Ashworth A. Lord CJ, et al. Nature. 2012 Jan 18;481(7381):287-94. doi: 10.1038/nature10760. Nature. 2012. PMID: 22258607 Review.
Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study.
Ang JE, Gourley C, Powell CB, High H, Shapira-Frommer R, Castonguay V, De Greve J, Atkinson T, Yap TA, Sandhu S, Banerjee S, Chen LM, Friedlander ML, Kaufman B, Oza AM, Matulonis U, Barber LJ, Kozarewa I, Fenwick K, Assiotis I, Campbell J, Chen L, de Bono JS, Gore ME, Lord CJ, Ashworth A, Kaye SB. Ang JE, et al. Among authors: lord cj. Clin Cancer Res. 2013 Oct 1;19(19):5485-93. doi: 10.1158/1078-0432.CCR-13-1262. Epub 2013 Aug 6. Clin Cancer Res. 2013. PMID: 23922302
255 results